IMDC / Heng Risk Model (Metastatic RCC)

Counts six routine clinical and laboratory risk factors to stratify metastatic renal cell carcinoma patients starting systemic therapy into favorable, intermediate, or poor prognostic groups, supporting first-line treatment selection and trial risk-stratification.

Time from diagnosis to systemic therapy < 1 year (strict <; exactly 1 year or longer scores 0)

Karnofsky Performance Status < 80% (strict <; KPS exactly 80% scores 0)

Hemoglobin < lower limit of normal (LLN) (strict <)

Corrected (albumin-adjusted) calcium > upper limit of normal (strict >; surrogate > 10.0 mg/dL when no lab ULN; exactly 10.0 mg/dL scores 0)

Neutrophils > upper limit of normal (strict >)

Platelets > upper limit of normal (strict >)